リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Role of serum n-6 polyunsaturated fatty acids in the development of acute coronary syndromes」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Role of serum n-6 polyunsaturated fatty acids in the development of acute coronary syndromes

Inoue, Naoya Morikawa, Shuji Murohara, Toyoaki 名古屋大学

2023.08

概要

With the advent of a super-aging society in Japan, the proportion of young people with acute
coronary syndrome (ACS), has relatively decreased due to the increasing number of elderly
people. On the contrary, the age-adjusted incidence of acute myocardial infarction (AMI) over the
past 30 years has been increasing particularly among men.1 In addition, the clinical characteristics
and outcomes of ACS among individuals aged below 45 years differ from those of middle-aged
and older patients due to differences in lifestyle habits including diet.2 Therefore, the new risk
factors for ACS correlated with lifestyle habits, particularly diet, should be identified.
Several investigators have shown that the relationship between coronary artery disease (CAD)
and polyunsaturated fatty acids (PUFAs) converted from essential fatty acids such as linoleic
acid (LA) and a-linolenic acid.3-8 First, low serum n-3 PUFA levels are associated with a high
incidence of cardiovascular events and mortality.3,4 In particular, the eicosapentaenoic acid (EPA)/
arachidonic acid (AA) ratio is a good indicator of cardiovascular events even in patients with
diabetes mellitus who experienced post-myocardial infarction, as it is not affected by statins.5 In
addition, a low EPA/AA ratio is significantly correlated with the development of ACS.6
However, previous reports have focused on increasing the serum concentrations of n-3 PUFAs
from seafood, plant sources, and supplements and, consequently, reducing the risk of developing
CAD by preventing a decrease in the EPA/AA ratio.3,4,6 Interestingly, one of these results showed
that biomarkers of n-3 PUFAs are associated with a lower risk of incident fatal CAD but not
nonfatal MI.7 Furthermore, in a systematic review of the association between n-6 polyunsaturated
fatty acids and CAD, the benefit of increasing n-6 remains unclear.8
This case-control study aimed to compare the PUFA levels between the ACS and staged
groups. By comprehensively comparing serum n-6 PUFAs as well as n-3 PUFAs and multiple
lipid levels and their respective ratios and the use of strong statins, we examined the use of
serum n-6 PUFAs to prevent ACS. ...

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1 Takii T, Yasuda S, Takahashi J, et al. Trends in acute myocardial infarction incidence and mortality over

30 years in Japan: Report from the Miyagi-AMI registry study. Circ J. 2010;74(1):93–100. doi:10.1253/

circj.CJ-09-0619.

2 Jinnouchi H, Sakakura K, Wada H, et al. Clinical features of myocardial infarction in young Japanese

patients. Int Heart J. 2013;54(3):123–128. doi:10.1536/ihj.54.123.

3 Amano T, Matsubara T, Uetani T, et al. Impact of omega-3 polyunsaturated fatty acids on coronary plaque

instability: An integrated backscatter intravascular ultrasound study. Atherosclerosis. 2011;218(1):110–116.

doi:10.1016/j.atherosclerosis.2011.05.030.

4 Hara M, Sakata Y, Nakatani D, et al. Low levels of serum n-3 polyunsaturated fatty acids are associated with

worse heart failure-free survival in patients after acute myocardial infarction. Circ J. 2013;77(1):153–162.

doi:10.1253/circj.CJ-12-0875.

5 Takahashi M, Ando J, Shimada K, et al. The ratio of serum n-3 to n-6 polyunsaturated fatty acids is

associated with diabetes mellitus in patients with prior myocardial infarction: A multicenter cross-sectional

study. BMC Cardiovasc Disord. 2017;17(1):41. doi:10.1186/s12872-017-0479-4.

6 Nishizaki Y, Shimada K, Tani S, et al. Significance of imbalance in the ratio of serum n-3 to n-6

polyunsaturated fatty acids in patients with acute coronary syndrome. Am J Cardiol. 2014;113(3):441–445.

doi:10.1016/j.amjcard.2013.10.011.

7 Del Gobbo LC, Imamura F, Aslibekyan S, et al. w-3 polyunsaturated fatty acid biomarkers and coronary

heart disease: Pooling project of 19 cohort studies. JAMA Intern Med. 2016;176(8):1155–1166. doi:10.1001/

jamainternmed.2016.2925.

8 Hooper L, Al-Khudairy L, Abdelhamid AS, et al. Omega-6 fats for the primary and secondary prevention of

cardiovascular disease. Cochrane Database Syst Rev. 2018;7(7):CD011094. doi:10.1002/14651858.CD011094.

pub3.

9 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow

Transplant. 2013;48(3):452–458. doi:10.1038/bmt.2012.244.

10 Arashi H, Yamaguchi J, Kawada-Watanabe E, et al. Polyunsaturated fatty acid impact on clinical outcomes

in acute coronary syndrome patients with dyslipidemia: Subanalysis of HIJ-PROPER. J Am Heart Assoc.

2019;8(16):e012953. doi:10.1161/JAHA.119.012953.

11 Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clin Res Cardiol.

2017;106(4):237–248. doi:10.1007/s00392-016-1069-7.

12 Hoover LE. Cholesterol management: ACC/AHA updates guideline. Am Fam Physician. 2019;99(9):589–591.

13 Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and

cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the

Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255–323. doi:10.1093/eurheartj/ehz486.

14 Amioka N, Miyoshi T, Otsuka H, et al. Serum malondialdehyde-modified low-density lipoprotein levels on

admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary

intervention. J Cardiol. 2019;74(3):258–266. doi:10.1016/j.jjcc.2019.02.012.

15 Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: A science advisory from the American Heart

Association. Circulation. 2017;135(15):e867-e884. doi:10.1161/CIR.0000000000000482.

16 Domei T, Yokoi H, Kuramitsu S, et al. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the

incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ

J. 2012;76(2):423–429. doi:10.1253/circj.CJ-11-0941.

17 Maki KC, Eren F, Cassens ME, Dicklin MR, Davidson MH. w-6 polyunsaturated fatty acids and cardiometabolic health: Current evidence, controversies, and research gaps. Adv Nutr. 2018;9(6):688–700. doi:10.1093/

advances/nmy038.

18 Sergeant S, Rahbar E, Chilton FH. Gamma-linolenic acid, Dihommo-gamma linolenic, Eicosanoids and

inflammatory processes. Eur J Pharmacol. 2016;785:77–86. doi:10.1016/j.ejphar.2016.04.020.

19 Al-Hilal M, Alsaleh A, Maniou Z, et al. Genetic variation at the FADS1-FADS2 gene locus influences delta-5

desaturase activity and LC-PUFA proportions after fish oil supplement. J Lipid Res. 2013;54(2):542–551.

doi:10.1194/jlr.P032276.

20 Park S, Lee S, Kim Y et al. Causal Effects of Serum Levels of n-3 or n-6 polyunsaturated fatty acids

on coronary artery disease: Mendelian Randomization Study. Nutrients. 2021;13(5):1490. doi:10.3390/

nu13051490.

References End

Nagoya J. Med. Sci. 85. 592–601, 2023

601

doi:10.18999/nagjms.85.3.592

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る